INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, inc. - BLUE

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by bluebird bio and its officers or directors following a significant drop in stock price after an acquisition announcement [1][3]. Group 1: Acquisition Details - On February 21, 2025, bluebird bio announced a definitive agreement to be acquired by Carlyle and SK Capital, with stockholders set to receive $3.00 per share in cash and a contingent value right potentially worth up to$6.84 per share, contingent on achieving $600 million in net sales by December 31, 2027 [2]. - The acquisition was described as the "only viable solution to generate value for stockholders" after the FDA denied bluebird's appeal for a priority review voucher for the third time, which jeopardized the company's debt covenants [2]. Group 2: Stock Price Reaction - Following the acquisition announcement, bluebird's stock price fell by$2.96, or 42.05%, closing at $4.08 per share on February 21, 2025 [3].